Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 300 IN PLASTIC CONTAINER versus IOPAMIDOL 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 300 IN PLASTIC CONTAINER versus IOPAMIDOL 370.
IOPAMIDOL-300 IN PLASTIC CONTAINER vs IOPAMIDOL-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a non-ionic, low-osmolality iodinated contrast agent that increases the radiopacity of vascular structures and tissues by attenuating X-rays. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Iopamidol is a nonionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. Its mechanism is physical rather than pharmacological, based on iodine content and osmolality.
Intravenous administration: 1-2 mL/kg (300-600 mg iodine/kg) for contrast imaging; maximum 200 mL per procedure.
1-2 mL/kg (370 mg iodine/mL) IV up to a maximum of 150 mL per procedure for contrast-enhanced CT; for angiography, dose varies by procedure.
None Documented
None Documented
Approximately 2 hours in patients with normal renal function (GFR >90 mL/min). Prolonged in renal impairment (up to 30 hours or more in severe disease).
Terminal elimination half-life is approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function. Prolonged to 10-70 hours in patients with renal impairment, necessitating dose adjustment or avoidance.
Primarily renal via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
Primarily renal; >90% of administered dose excreted unchanged in urine via glomerular filtration within 24-48 hours. Less than 1% excreted in feces or bile.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent